I had a follow-up call with Dr. Kumar, CEO of ITUS, today. Basically, I was looking to understand more about the benign versus cancerous tumor diagnosing being performed by ITUS. We covered this and a few other points. Here...
Last week, ITUS reported data on a study of their novel cancer diagnostic, C-Chek. I had the opportunity to check in and discuss this data, and other corporate developments, with the Company's CEO, Dr. Amit Kumar. Tailwinds (TW):  Lets get...
The path to being a good investor is to be able to see what the future holds and place your bets accordingly. If you can do so often, you'll have a portfolio of winners. It's an easy game, right? There...
Tailwinds' Take: as ITUS continues to show clinical success on Cchek, protecting the IP will be critical to maintaining the incredible TAM. ITUS' patent strategy is solidifying their position as the leading player in using a Neural Network in...
Tailwinds' Take: additional data from the ongoing ResearchDx partnership, which is intended to certify Cchek as a CLIA approved diagnostic, will be presented. Anixa remains on track to deliver their novel AI based prostate diagnostic to the market by...
Tailwinds’ Take: Dr. Ostuni joining the Scientific Advisory Board (SAB) of Anixa could have major significance to the Company. Investors should really start paying attention to the recent additions to the SAB as they are telling signals into the...
Tailwinds' Take: this is positive for a couple reasons. Oral presentations are not handed out willy-nilly...it shows that the medical community is catching on to Anixa and excited about what they're doing. Also, since it's on benign data, which...
As we enter the new year it is very difficult not to be optimistic...borderline exuberant. The Tailwinds Select Portfolio has been on a tear lately, closing the year with a bang. If gaining 20% in the last two months...
Tailwinds' Take: another oral presentation, at a key conference no less, is going to help Cchek gain recognition right before its launch. Interestingly, data on other cancers than prostate and breast will be presented. This is a very positive...
SAN JOSE, Calif., July 17, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that it has established a strategic alliance and license agreement with Cleveland Clinic for an innovative...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.